Revitope, Junshi Biosciences enter into research collaboration to develop first-in-class dual-antigen targeting cancer therapies

Revitope Oncology | July 14, 2020

Revitope Oncology Inc ("Revitope Oncology")., a biotechnology company advancing a new class of precision cancer immunotherapies, its wholly-owned subsidiary Revitope Limited (Revitope Limited, together with Revitope Oncology, "Revitope") and Junshi Biosciences (1877.HK, 688180.SH), a leading innovation–driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the companies have entered into a strategic research collaboration. Revitope will leverage its proprietary protein engineering platform together with Junshi's novel antibody components to develop first-in-class dual-antigen targeting cancer therapies. Revitope is granting Junshi a world-wide exclusive license on products arising from the research collaboration and will receive up to $160 million in development and commercialization milestone payments for each T Cell Engaging Antibody Circuit (TEAC) molecule selected by Junshi, plus tiered royalties. Junshi also commits to making a direct equity investment in Revitope Oncology in the amount of $10M for 9.99% of total Revitope Oncology shares on an as-converted basis with terms and conditions to be mutually agreed and subject to compliance with all applicable laws.

Spotlight

NDA supported over 38% of the new medicinal products that were approved in the EU in 2014.

Spotlight

NDA supported over 38% of the new medicinal products that were approved in the EU in 2014.

Related News

MEDICAL

Bio-techne and Cygnus Technologies Present Plex Hek 293 Hcp 3G Immunoassay

Bio-Techne Corporation | April 13, 2022

Bio-Techne Corporation launched 3G assay for automated process impurity assessment on the EllaTM immunoassay platform ( NASDAQ: TECH ) and Cygnus Technologies, a division of Maravai LifeSciences ( NASDAQ: MRVI ). In cell and gene therapy applications, the purification of viral particles to reduce host cell protein (HCP) contamination is an important part of the viral production workflow. To guarantee HCP impurity clearance is performed in compliance with regulatory criteria, accurate quantification throughout process phases is required. The novel Simple Plex HEK 293 HCP 3G test uses a cartridge-based microfluidic design to deliver uniform and controlled assay conditions for HCP detection that is extremely accurate and reproducible. The test has a hands-free procedure and provides data in 90 minutes, providing pharmaceutical developers with a reliable and convenient tool for HCP impurity quantification. Simple Plex assays on the Ella platform, classic immunoassay methods, provide built-in calibration to reduce set-up time and user-dependent variability. The gold standard in HEK 293 HCP impurity quantification is Cygnus Technologies' HEK 293 HCP ELISA Kit, 3G. With high-tech antibody affinity extraction and heavy spectrometry procedures, the kit's antibody was tested for reactivity to almost 3,000 distinct HCPs present in HEK 293 strains. The kit has been tested with various viral vector-based medicinal compounds and in-process samples, demonstrating that it possesses the specificity and sensitivity to detect HEK 293 HCP contaminants with the reproducibility needed to meet regulatory requirements. The Simple Plex HEK 293 HCP 3G assay uses the same HEK 293 HCP antibodies from market leader Cygnus Technologies, ensuring the Cygnus ELISA's extensive HCP detection coverage and industry-recognized specificity, as well as the automated Ella platform's workflow advantages. We continue to enjoy the fruits of the Bio-Techne-Cygnus Technologies partnership as it provides the therapeutic development and manufacturing community an automated platform-based approach for HEK 293 host cell impurity testing, Fast and efficient process development and monitoring is crucial for biopharmaceutical companies providing a safe and efficacious product in a cost-effective manner." Will Geist, President of Bio-Techne's Protein Sciences Segment.

Read More

BGN Technologies Announces Research Collaboration Agreement with ECOIBÉRIA in the Field of Plastic Recycling by Bacteria

BGN Technologies | November 05, 2020

BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev (BGU), announced today that it had signed a research collaboration agreement with ECOIBÉRIA in the field of plastic recycling by bacteria, based on research from the team of Prof. Ariel Kushmaro and Prof. Alex Sivan, both from the Laboratory of Environmental Biotechnology and Avram and Stella Goldstein-Goren Department of Biotechnology Engineering at BGU. Polyethylene terephthalate (PET) is the most abundantly used polymer in the world, with multiple applications in the textile industry as well as in food and beverage packaging. It is estimated that about 56 million tons of PET are produced yearly worldwide, mostly as single use packaging material. Therefore, intense efforts are directed towards recycling and reuse of the PET plastic materials. Prof.'s Kushmaro and Sivan and their team have been studying plastic biodegradation and have discovered several bacteria species that are able to biodegrade polyethylene, which was previously considered a non-biodegradable plastic mainly because of the highly stable carbon−carbon (C−C) bonds of the polymer backbone. Based on these findings, the research collaboration project will assess the biodegradation of PET by previously identified bacteria as well as novel ones, with the aim of developing an efficient biodegradation process of PET whose products will be used as raw materials for recycled PET in the future.

Read More

MEDICAL

Sesen Bio Partners with Hikma Pharmaceuticals for the Registration and Commercialization of Vicineum

Sesen Bio | December 02, 2020

Sesen Bio, a late-stage clinical organization creating focused on combination protein therapeutics for the therapy of patients with cancer, and Hikma Pharmaceuticals, a worldwide pharmaceutical organization and driving permitting partner in the Middle East and North Africa ("MENA") area spend significant time in the turn of events and commercialization of an expansive scope of great medicines, today declared that the organizations have gone into exclusive licensing agreement for the registration and commercialization of Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer ("NMIBC") and different sorts of cancer in MENA. Vicineum, a privately managed combination protein, is Sesen Bio's lead product competitor presently in the subsequent phase of a Phase 3 enrollment preliminary for the treatment of high-hazard, BCG-unresponsive NMIBC. In December 2019, the Company started the BLA submission for Vicineum to the FDA under Rolling Review. Under the details of the understanding, Sesen Bio granted Hikma a exclusive license to register and commercialize Vicineum in all of the 19 MENA markets in a course of action foreseen to convey equivalent worth offer to the two players. Monetary terms of the arrangement are secret and incorporate a forthright installment to Sesen Bio, deals related achievement installments, and eminences on net deals in the locale for the term of the understanding. Sesen Bio holds full turn of events and commercialization rights for Vicineum for the treatment of NMIBC in the US and the remainder of the world barring Greater China and MENA.

Read More